Literature DB >> 29547083

Relationship between external ventricular drain clamp trials and ventriculoperitoneal shunt insertion following nontraumatic subarachnoid hemorrhage: a single-center study.

Luis C Ascanio1, Raghav Gupta1, Nimer Adeeb2, Justin M Moore1,3, Christoph J Griessenauer4, Julie Mayeku1, Yaw Tachie-Baffour1, Ranjit Thomas1, Abdulrahman Y Alturki1,5, Philip G R Schmalz6, Christopher S Ogilvy1, Ajith J Thomas1.   

Abstract

OBJECTIVE: Currently, there is no established standard regarding the ideal number of external ventricular drain (EVD) clamp trials performed before ventriculoperitoneal (VP) shunt insertion following nontraumatic subarachnoid hemorrhage (SAH). In this study, the authors aimed to evaluate this relationship.
METHODS: A retrospective review of all patients presenting with SAH between July 2007 and December 2016 was performed. Patients with SAH who had received an EVD within the first 24 hours of hospital admission and had undergone at least 1 clamp trial prior to EVD removal were eligible for inclusion in the study. Patient demographics, clinical presentations, SAH etiologies and grades, clamp trial data, hospital lengths of stay, and functional outcomes were recorded.
RESULTS: One hundred fourteen patients with nontraumatic SAH complicated by posthemorrhagic hydrocephalus were included in the study. The median patient age was 57 years (range 28-90 years), with a male/female ratio of 1:1.7. A ruptured aneurysm was the underlying etiology of SAH in 79.8% of patients. A majority of patients (69.4%) had a Hunt and Hess grade III-V on admission. The median number of clamp trials performed was 2 (range 1-6). A VP shunt was required in 40.4% of patients. In those who underwent 2 and 3 clamp trials, 60% and 38.9%, respectively, did not require subsequent VP shunt placement.
CONCLUSIONS: Surgical placement of a VP shunt is associated with complications. Clamp trials are routinely performed before making the decision to insert a shunt. In the present study, the authors found that a significant percentage of patients passed their second and third clamp trials without requiring subsequent shunt insertion. These data support performing multiple clamp trials prior to shunt placement.

Entities:  

Keywords:  CSF = cerebrospinal fluid; EVD = external ventricular drain; GCS = Glasgow Coma Scale; HH = Hunt and Hess; ICP = intracranial pressure; SAH = subarachnoid hemorrhage; VP = ventriculoperitoneal; WFNS = World Federation of Neurosurgical Societies; clamp trials; external ventricular drain; hydrocephalus; subarachnoid hemorrhage; vascular disorders; ventriculoperitoneal shunt

Mesh:

Year:  2018        PMID: 29547083     DOI: 10.3171/2017.10.JNS171644

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  4 in total

Review 1.  Evidence-Based Management of External Ventricular Drains.

Authors:  David Y Chung; DaiWai M Olson; Sayona John; Wazim Mohamed; Monisha A Kumar; Bradford B Thompson; Guy A Rordorf
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-26       Impact factor: 5.081

Review 2.  External ventricular drain management in subarachnoid haemorrhage: a systematic review and meta-analysis.

Authors:  Joanna Palasz; Linda D'Antona; Sarah Farrell; Mohamed A Elborady; Laurence D Watkins; Ahmed K Toma
Journal:  Neurosurg Rev       Date:  2021-08-26       Impact factor: 3.042

3.  Association of External Ventricular Drain Wean Strategy with Shunt Placement and Length of Stay in Subarachnoid Hemorrhage: A Prospective Multicenter Study.

Authors:  David Y Chung; Bradford B Thompson; Monisha A Kumar; Ali Mahta; Shyam S Rao; James H Lai; Aleksey Tadevosyan; Kathryn Kessler; Joseph J Locascio; Aman B Patel; Wazim Mohamed; DaiWai M Olson; Sayona John; Guy A Rordorf
Journal:  Neurocrit Care       Date:  2021-09-08       Impact factor: 3.532

4.  Quantitative Modeling of External Ventricular Drain Output to Predict Shunt Dependency in Aneurysmal Subarachnoid Hemorrhage: Cohort Study.

Authors:  A Perry; C S Graffeo; G Kleinstern; L P Carlstrom; M J Link; A A Rabinstein
Journal:  Neurocrit Care       Date:  2020-08       Impact factor: 3.210

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.